IndustryCompany release

CapsoVision Q3 revenue rises to $3.6M as FDA-cleared AI Highlights tool launches in US

🇺🇸 CapsoVision, Inc (CV) · Thu 12 Nov 2026

The capsule endoscopy maker reported a $7.3M quarterly net loss, completed enrolment in its CapsoCam Colon study and raised about $17.8M net in September.

CapsoVision reported third-quarter revenue of $3.6M on 12 November 2026, up slightly from $3.5M in the same period a year earlier. The company posted a net loss of $7.3M for the quarter.

The US Food and Drug Administration cleared AI Highlights on 25 September. The tool is an AI-assisted reading aid for the CapsoCam Plus capsule endoscope. CapsoVision began its US launch on 2 November.

The company also said enrolment in its CapsoCam Colon study is complete. It is targeting a 510(k) submission by the end of 2026. A 510(k) is the premarket notification route through which US device makers show that a product is substantially equivalent to a legally marketed device.

On the financing side, CapsoVision raised about $17.8M net through a registered direct offering in September. The summary available does not give further detail on how the proceeds will be used.

What it means for your team

  • AI-assisted reading tools for capsule endoscopy are now reaching the US market through FDA clearance, which is relevant for teams tracking software-enabled device pathways.
  • A 510(k) submission for CapsoCam Colon is targeted for year-end 2026; the timing of any FDA decision will depend on the agency's review.
  • Revenue growth was modest and the company remains loss-making, so commercial uptake of AI Highlights will be a point to watch for market-access teams.

Company's press release (SEC filing): CapsoVision, Inc ↗

Article written by VigiEye from the official source (CapsoVision, Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →